Folinic acid

CLINICAL USE


Folinic acid rescue Enhancement of 5-fluorouracil cytotoxicity in advanced colorectal cancerFolate deficiency

DOSE IN NORMAL RENAL FUNCTION

Varies according to indication

PHARMACOKINETICS

  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :511.5
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :54
  • %Excreted unchanged in urine &nbsp &nbsp : 80–90 (as inactive metabolites)

  • Volume of distribution (L/kg) &nbsp &nbsp &nbsp :17.5

  • half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :32–35 minutes/–

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Some removal likely. Dose as in normal renal function

  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Some removal likely. Dose as in normal renal function
  • HDF/high flux &nbsp :Dialysed. Dose as in normal renal function
  • CAV/VVHD &nbsp &nbsp &nbsp:Some removal likely. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugsShould not be administered simultaneously with a folic acid antagonist as this may nullify the effect of the antagonist

    ADMINISTRATION

    Reconstition

    For

    IV infusion

    , compatible with: sodium chloride 0.9%, glucose 5%, sodium lactate injection

    Route

    IM, IV injection,

    IV infusion

    , oral

    Rate of Administration

    Because of the calcium content of leucovorin solutions, no more than 160 mg/minute should be injected IV

    Comments


    Tags:

    • Related News

    sotalol hydrochloride.txt

    tazocin.txt